Evidence map›Paper›PMID 33238999›Full record

ArticleMalaria journal2020

Intermittent screening and treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy: implementation feasibility in a routine healthcare system setting in western Kenya.

Jenny Hill, Peter Ouma, Seth Oluoch, Jane Bruce, Simon Kariuki, Meghna Desai, Jayne Webster

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Jenny HillDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK. jenny.hill@lstmed.ac.uk.ORCID http://orcid.org/0000-0003-1588-485X
Peter OumaKenya Medical Research Institute/Centre for Global Health Research, Kisumu, Kenya.
Seth OluochKenya Medical Research Institute/Centre for Global Health Research, Kisumu, Kenya.
Jane BruceDisease Control Department, London School of Tropical Medicine and Hygiene, London, UK.
Simon KariukiKenya Medical Research Institute/Centre for Global Health Research, Kisumu, Kenya.
Meghna DesaiCenters for Disease Control and Prevention, Atlanta, GA, USA.
Jayne WebsterDisease Control Department, London School of Tropical Medicine and Hygiene, London, UK.
Kenya Medical Research Institute · KECenters for Disease Control and Prevention · USLiverpool School of Tropical Medicine · GB

Funding

Bill and Melinda Gates Foundation OPP46099
6 · The paper itself

Abstract

backgroundIntermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended for preventing malaria in pregnancy in areas of moderate-to-high transmission in sub-Saharan Africa. However, due to increasing parasite resistance to SP, research on alternative strategies is a priority. The study assessed the implementation feasibility of intermittent screening and treatment (ISTp) in the second and third trimester at antenatal care (ANC) with malaria rapid diagnostic tests (RDTs) and treatment of positive cases with dihydroartemisinin-piperaquine (DP) compared to IPTp-SP in western Kenya.

methodsA 10-month implementation study was conducted in 12 government health facilities in four sub-counties. Six health facilities were assigned to either ISTp-DP or IPTp-SP. Evaluation comprised of facility audits, ANC observations, and exit interviews. Intermediate and cumulative effectiveness analyses were performed on all processes involved in delivery of ISTp-DP including RDT proficiency and IPTp-SP ± directly observed therapy (DOT, standard of care). Logistic regression was used to identify predictors of receiving each intervention.

resultsA total of 388 and 389 women were recruited in the ISTp-DP and IPTp-SP arms, respectively. For ISTp-DP, 90% (289/320) of eligible women received an RDT. Of 11% (32/289) who tested positive, 71% received the correct dose of DP and 31% the first dose by DOT, and only 6% were counselled on subsequent doses. Women making a sick visit and being tested in a facility with a resident microscopist were more likely to receive ISTp-DP (AOR 1.78, 95% CI 1.31, 2.41; and AOR 3.75, 95% CI 1.31, 2.40, respectively). For IPTp-SP, only 57% received a dose of SP by DOT. Payment for a laboratory test was independently associated with receipt of SP by DOT (AOR 6.43, 95% CI 2.07, 19.98).

conclusionsThe findings indicate that the systems effectiveness of ANC clinics to deliver ISTp-DP under routine conditions was poor in comparison to IPTp-SP. Several challenges to integration of ISTp with ANC were identified that may need to be considered by countries that have introduced screening at first ANC visit and, potentially, for future adoption of ISTp with more sensitive RDTs. Understanding the effectiveness of ISTp-DP will require additional research on pregnant women's adherence to ACT.

Indexed as

AdolescentAdultAntimalarialsArtemisininsDiagnostic Tests, RoutineDrug CombinationsFeasibility StudiesFemaleHumansKenyaMalariaMass ScreeningMiddle AgedPiperazinesPregnancyPregnancy Complications, ParasiticAntimalarialsArtemisininsartenimolDrug CombinationspiperaquinePiperazinesQuinolinesDihydroartemisinin-piperaquineHealth providersHealth system deliveryIntermittent preventive treatmentIntermittent screening and treatmentKenyaPregnant women

Identifiers

PMID33238999
PMCPMC7690090
OpenAlexW3109476037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.